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Abstract Invasive fungal infections (IFI) are a significant
cause of morbidity and mortality in the immunocompro-
mised. The traditional diagnostic methods of culture and
histological examination lack sensitivity and often only
make a diagnosis late when the fungal burden is high,
reducing the chances of cure even with the availability of
new more potent and less toxic antifungal agents. New non-
culture-based serological and PCR assays have been devel-
oped. These appear more sensitive and are able to make an
earlier diagnosis as compared with traditional diagnostic
methods. Early diagnosis is central to reducing IFI-related
morbidity and mortality. This review describes the diagnos-
tic potential of the new serological and PCR assays and
outlines how these assays have been incorporated into algo-
rithms to improve the management of IFI.
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Introduction
Invasive fungal infections (IFI) remain as a major cause of
mortality in those undergoing hematopoietic stem cell or solid
organ transplantation, chemotherapy for hematological malig-
nancies, patients in intensive care units (ICU) and those who
are HIV infected. Candida is now the fourth most common
cause of bloodstream infections and invasive candidiasis (IC)
has been associated with an attributable mortality of 49 % in
some ICUs in the United States of America (USA)[1, 2]. More
recently, mortality rates of up to 60 % have been reported with
invasive Aspergillus infections in high-risk hematology
patients [3, 4•]. The numbers that die from cryptococcal men-
ingitis (CM) is estimated at 625,000 with 80 % (500,000) of
these deaths occurring in sub-Saharan Africa [5•].
The economic costs of IFI are also substantial. In the USA
the mean total hospital costs of invasive aspergillosis (IA)
have been estimated at US$96,310 [6]. A study performed
in one Australian center reported that treatment of IFI in
allogeneic hematopoietic stem cell transplantation (HSCT)
recipients and patients with acute myeloid leukemia was esti-
mated at AU$30,957/case, increasing to AU$80,291/case if
admitted to ICU, as compared to matched controls [7].
These high mortality rates and economic costs occur de-
spite the availability of antifungal agents with improved po-
tency and less toxicity. Early treatment has been related to
improved outcomes but this is dependent on diagnostic tests
that are both rapid and highly sensitive [8]. As traditional
culture- and histology-based diagnostic methods have poor
sensitivity and often only make a diagnosis late when the
fungal burden is high, research has turned its focus in the last
two decades to the development of serological and molecular
assays with improved accuracy and rapidity of diagnosis [9].
This review will focus on the diagnostic capabilities of
new serological and molecular assays and how these assays
are incorporated into screening and pre-emptive (or as more
accurately renamed diagnostic-driven (DD)) strategies for
improved management of IFI.
Serological Markers for the Diagnosis of IFI
(1→3)-β-D-Glucan (BDG)
The BDG, a polysaccharide cell wall component of many
fungi including Candida, Aspergillus and Fusarium, is
C. O. Morrissey (*)
Infectious Diseases Unit, Alfred Health, Level 2, Burnet Building,
85 Commercial Road,
Melbourne, Victoria 3004, Australia
e-mail: o.morrissey@alfred.org.au
C. O. Morrissey
Department of Infectious Diseases, Central Clinical School,
Monash University, Melbourne, Australia
Curr Fungal Infect Rep (2013) 7:51–58
DOI 10.1007/s12281-012-0128-4
released during invasive infection. Four commercial tests
have been developed for the detection of BDG including
Fungitell (Associates of Cape Cod, East Falmouth, MA,
USA), Fungitec-G (Seikagaku Cooperation, Tokyo, Japan),
Wako-WB003 assay (Wako Pure Chemical Industries,
Osaka, Japan) and Maruha (Maruha-Nichizo Foods Inc,
Tokyo, Japan). These kits vary according to cut-off value
used for a positive result and the detection method (colori-
metric or turbimetric). The BDG is detected in a patient’s
serum by incubating serum with lyophilized horseshoe crab
coagulation factor. If BDG is present, then the coagulation
cascade is initiated.
The BDG assay has been extensively examined for its
diagnostic performance in patients undergoing chemothera-
py for hematological malignancies. A recent meta-analysis
reported variable sensitivity and specificity (50 %-8 5 % and
80 %-99 %, respectively) [10••]. This variability is due to
the heterogeneity of study designs and the populations in-
cluded. The BDG has also been shown to make an earlier
diagnosis of IFI as compared with culture by a median of 5–
10 days [11, 12]. As a result, BDG assay has been included
as an indirect microbiological criterion in the European
Organization for Research and Treatment of Cancer/Myco-
ses Study Group (EORTC/MSG) definitions of IFI and has
been recommended for use in clinical trials and routine
clinical practice by the European Conference on Infections
in Leukemia (ECIL) guidelines [13, 14•].
The BDG has been less extensively examined in ICU
patients. Posteraro et al., examined the diagnostic perfor-
mance of the assay for IC in critically-ill ICU patients and
compared it to the Candida score and colonization index of
Leon and Pittet, respectively [15••, 16, 17]. The diagnostic
accuracy was found to be greater for a single positive BDG
value of >80 pg/ml (cut-off of Fungitell assay) as compared
with the Candida score and colonization index (receiver
operating characteristic (ROC) area under the curve (AUC)
0.98, 0.80 and 0.63, respectively). The sensitivity, specific-
ity, positive predictive value (PPV) and negative predictive
value (NPV) were 93.7 %, 83.6 %, 75 % and 98.6 %,
respectively. In addition, BDG was detected 1–3 days prior
to blood culture detection.
The evaluation of the BDG assay in bronchoalveolar
lavage (BAL) fluid has been very limited, especially in
comparison to galactomannan and PCR. The PPV was low
(20.0 %) for 109 immunocompromised cases of proven,
probable or possible IFI detected using the EORTC/MSG
definitions [18]. In comparison to Candida PCR, the Fungi-
tell BDG assay has been reported as having lower sensitivity
for IC (80% vs. 56%; p=0.03), with similar specificity
(70 % vs. 73 %; p=0.31) [19••].
Glucan is ubiquitous in the environment so false positiv-
ity can occur in patients undergoing hemodialysis or given
blood products using cellulose materials, surgical patients in
contact with cotton gauze, receiving β-lactam antibiotics
and with bacteremia. Levels decline with antifungal therapy
and a reduction in BDG levels with antifungal therapy has
been associated with improved survival. However, the assay
is not available in many institutions and is costly. Based on
studies to date, the current role of the BDG assay is as an
adjunct microbiological test for the diagnosis of IC.
More recently, BDG has been used to diagnose Pneumo-
cystis jirovecii pneumonia (PJP). BDG is a component of
the cyst wall of P. jirovecii. In a bivariate meta-analysis of
14 studies that included 357 cases of PJP and 1723 controls
without PJP, the average sensitivity and specificity were
determined as 94.8% and 86.3%, respectively, with positive
and negative likelihood ratios (LR) of 6.9 and 0.06, respec-
tively [20]. The area under the hierarchical summary ROC
curve was 0.97. This study indicates that BDG may have
potential for the diagnosis of PJP but further clinical evalu-
ation is required.
Candida Mannan Assays
Mannan is a polysaccharide cell wall component of Candida
and is released into blood during IC.Candidamannan antigen
and antimannan antibody assays (Platelia Candida Antigen
and Antibody assays) are commercially available from Bio-
Rad (Marnes-la-Coquette, France) in Europe only. The cut-
offs for test positivity are defined as 0.5 ng/mL for mannan
and 10 arbitrary units/mL for antimannan antibody. Values of
0.25-0.5 ng/mL and 5–10 arbitrary units/mL are considered as
indeterminate. Use of both tests in parallel improves sensitiv-
ity. A review published by ECIL showed that the sensitivity of
the mannan antigen and antimannan antibody assays when
used individually were 58% and 59%, respectively, but when
used together, the sensitivity increased to 83 % with no
significant reduction in specificity [21]. Based on these data
it is now recommended that the tests are used in combination
to diagnose IC. In addition, the assays performance varies
according to Candida species. It performs best for C. albicans
(sensitivity of 80–100 %), followed by C. glabrata and C.
tropicalis, and it performs least well for C. parapsilosis andC.
krusei (sensitivity of 40–50 %).
Bio-Rad has developed new detection assays, namely,
Platelia Candida Ag Plus (Ag-Plus) and the Platelia Candida
Ab Plus (Ab-Plus) which have been evaluated using a collec-
tion of stored serum samples obtained from 21 patients with
microbiologically proven IC and 30 controls [22•]. All
patients included in this study were undergoing myeloablative
chemotherapy for hematological malignancies. The sensitivity
and time to detection of IC were not significantly better than
for the conventional Platelia Candida assays and specificity
was reduced by 50 %. The reduction in specificity was deter-
mined by logistic regression analysis to be due to the detection
of cases of superficial candidiasis by the Ag-Plus assay.
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In a retrospective study of 45 patients either the Platelia
Candida Antigen and Antibody assays were positive a mini-
mum of two days prior to blood cultures. In addition, the
performance depends on the patient population and the phase
of treatment. Non-neutropenic surgical patients are more likely
to have positive antibodies firstly but neutropenic populations
undergoing chemotherapy are more likely to present with anti-
genemia [23]. Overall, further evaluation of the precise role of
Candidamannan antigen and antimannan antibody in different
populations is required before these assays are adopted into
clinical practice for use in diagnosing IC.
Galactomannan Assay
Galactomannan (GM) is a heat-stable polysaccharide pres-
ent in the cell wall of most Aspergillus species. It is also
present in the cell wall of some Penicillium species. During
invasive infection it is released from growing hyphae and
can be detected in bodily fluids including serum, BAL and
cerebrospinal fluid (CSF). Bio-Rad has developed a com-
mercially available assay, the Platelia Aspergillus GM
enzyme-immunosorbent assay (EIA). The original cut-off
was an optical density index (ODI) of 1.5 but subsequently
the Food and Drug Administration (FDA) has approved a
lower ODI cut-off of 0.5 [24, 25]. Bio-Rad has very recently
released a new assay which has been validated for testing on
BAL as well as serum. There are no published data com-
paring both GM assays, unlike the comparison of the vari-
ous Platelia Candida mannan assays.
The GM-EIA has been extensively examined for the earlier
and more accurate diagnosis of IA in hematology patients.
The sensitivity has varied between studies from 33 % to
100 % [24]. Like BDG analysis, this variation is related to
differences in study design. In a meta-analysis the overall
sensitivity was determined as 71 % with a specificity of
89 % [26]. The PPV is low (26–53 %) but the assay has an
excellent NPV (95–98 %), indicating it may have more value
as a screening tool to exclude IA. Some studies have also
reported that GM can be detected a median of 5–8 days before
culture positivity or clinical or radiological signs are present
[27]. As a result it has been included as a microbiological
criterion in the revised EORTC/MSG definitions of IA [13].
Whilst an ODI cut-off for positivity of 0.5 for serum is
generally recommended it is less clear as to how many
positive serum samples are needed to classify a case as IA.
Maertens et al., found using ROC analysis that a cut-off of
0.5 in two sequential samples was associated with an opti-
mal sensitivity of 92.1 % [25]. As a result, it is recommen-
ded that a positive result (ODI>0.5 in serum) indicating IA
should be verified by retesting another aliquot of the same
sample or obtaining a new sample and demonstrating repro-
ducibility. Furthermore, studies have also indicated that the
Platelia Aspergillus EIA may be useful for determining
fungal burden and responses to antifungal therapy [28,
29]. The ODI values over time are strongly correlated with
treatment outcomes. Miceli et al., reported that the κ corre-
lation coefficient for the ODI and survival was significant at
0.87 (95 % confidence interval 0.814-0.93; p<0.001) [29].
The sensitivity of the GM-EIA is lower in solid organ
transplant recipients as compared with neutropenic and
HSCT recipients. The assay had a reported sensitivity of
56 % in liver transplant recipients and only 30 % in lung
transplant recipients indicating that this assay when used in
serum may not have a diagnostic role in these populations
[30, 31]. The assay has also been examined in serum samples
from HIV infected patients diagnosed with penicilliosis (15),
cryptococcosis (22) and 11 HIV infected patients with no IFI
(controls) [32]. The ODI was significantly elevated in those
with penicilliosis indicating that the test may have a role for
the early diagnosis of this infection in endemic areas.
The GM-EIA has also been evaluated in BAL. A meta-
analysis of 13 studies demonstrated that at a cut-off ODI of
0.5 the pooled diagnostic odds ratio (DOR), sensitivity,
specificity, positive and negative LR for proven or probable
IA of 52.7, 87 %, 89 %, 8.0, 0.15, respectively [33••]. When
a cut-off ODI of 1.0 was used the DOR (112.7), specificity
(95 %) and positive LR (17.0) increased with similar sensi-
tivity (86 %) and negative LR (0.15), indicating that for
BAL the optimal cut-off is 1.0. In addition, the sensitivity of
GM-EIA was higher in BAL as compared with its use in
serum (65 %) [33••].
Mold-active antifungal agents may decrease the perfor-
mance of GM-EIA causing false negative results [34]. False
positive results may occur in those on antibiotics (especially
piperacillin-tazobactam or amoxicillin-clavulanate), dialy-
sis, Plasmalyte solution, other fungal infections, myeloma
and neonates.
Cryptococcal Antigen-Based Assays
Cryptococcal polysaccharide antigens can be detected in
serum and CSF using latex agglutination (LA) or EIA
methods which are more sensitive than microscopy and
culture (93 % for the LA compared with 50–80 % for
microscopy) [35–38]. The LA required minimal laboratory
infrastructure and is easy to perform. Its distinct disadvan-
tage is its subjectivity related to reading the agglutination
reaction. The EIA is as sensitive as the LA. The EIA has
advantages over the LA. The EIA does not need pretreat-
ment of serum samples and has greater reproducibility as
results are generated objectively using a spectrophotometer
[35–37]. However, EIA requires technical expertise to per-
form and more advanced laboratory infrastructure. It is best
suited to larger reference and diagnostic laboratories.
More recently, a new cryptococcal antigen assay has been
developed, namely, the lateral flow assay (LFA; Immuno-
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Mycologics, Norman, OK, USA). The LFA detects crypto-
coccal antigen by dipping an immunochromatographic test
strip into a drop of diluted serum or CSF and incubating for
10minutes. A positive result is when two bands develop in the
test zone. The LFA has comparable sensitivity and specificity
to the LA and EIA and has received approval from regulatory
authorities both in Europe and USA for use in serum [39••].
The LFA may play a substantial role in the management of
CM in developing countries. It requires minimal training, can
be performed by non-laboratory staff and the assay requires no
refrigeration. In addition, Immuno-Mycologics have adopted
a global access pricing strategy such that it will be affordable
in developing countries.
Molecular-Based Diagnosis of IFI
The PCR assays have the potential for the rapid, sensitive
and early diagnosis of IFI. Many Candida- and Aspergillus-
specific as well as panfungal assays have been developed
for use in blood and other clinical specimens. Detailed
discussions of different PCR methods can be found in in
another recent review [40].
A meta-analysis of the use of PCR to diagnose IC has
reported a sensitivity ranging from 73–100 % and a speci-
ficity of 92–100 %, with pooled sensitivity and specificity
exceeding 90 % [41]. In this meta-analysis it was noted that
higher sensitivities were achieved by using whole blood
rather than serum samples, a commercial DNA extraction
kit, panfungal ribosomal RNA or multi-copy gene targets
and Candida- or fungal-specific PCR rather than multiplex
assays. Specificity was increased by testing serial samples.
Serial sampling and using consecutive results may assist in
differentiating between colonization and true invasive infec-
tion. Similar to other non-culture-based methods it appears
that PCR for IC diagnosis can make the diagnosis earlier
than blood cultures (median of three days) [42].
Aspergillus PCR assays have been used for screening
high-risk hematology patients with varying sensitivities
(63-100%). A meta-analysis of Aspergillus PCR assays for
use in blood has reported that high-risk hematology patients
should be screened twice-weekly and that a single PCR-
negative result rules out IA but to confirm IA two consec-
utively positive PCR results are recommended [43]. The
variation in sensitivity is not only related to study design
but also to the design of the PCR assay. A number of
technical factors have been determined as affecting sensi-
tivity and include DNA extraction methods (e.g., use of
bead-beating), and volume of blood tested [44, 45•, 46].
The diagnosis of IA by Aspergillus PCR assays has preced-
ed the diagnosis of IA by other methods (e.g., high resolu-
tion computed tomography (HRCT) scan and culture/
histological diagnosis by up to 3 weeks) [13, 47, 48].
Aspergillus PCR assays have also been examined and
compared to GM in BAL specimens [49••]. The ROC indi-
cated that a GM-ODI of 0.5 was optimal. Using this ODI,
sensitivity and specificity was higher for GM-EIA than for
Aspergillus PCR (79 % vs. 59 % and 96 % vs. 87 %, respec-
tively). Use of positive results from both assays to define IA
was associated with a sensitivity of 55 % and a specificity of
100 %. If either assay could be used to define IA, then the
sensitivity and specificity were calculated at 83 % and 83 %,
respectively. This indicates that if both tests are positive, then
IA is effectively confirmed and that the combined use of both
tests may improve the diagnosis of IFI.
There are conflicting data in the literature as to the effect
of antifungal therapy on the sensitivity of PCR assays in
both blood and BAL samples. Most report that Aspergillus-
active antifungal therapy reduces the sensitivity but others
have reported no effect [50–56]. This may be due, in part, to
the form that Aspergillus DNA circulates in the blood and to
the DNA extraction methodology. The PCR assays are
particularly prone to contamination by air-borne spores
which may result in false-positivity. Thus, a number of
procedures need to be implemented in the laboratory to
minimize contamination and the results need to be inter-
preted in the context of clinical and radiological findings.
A commercial Aspergillus PCR assay is available [57]. In
comparison to a validated in-house assay it has a sensitivity
of 60–70 % and a specificity of 90.5-100 %. The current
limitations of fungal PCR assays are that they are not stan-
dardized nor have they undergone extensive multi-center
clinical evaluation. As a result they are currently not includ-
ed as a mycological criterion in the EORTC/MSG defini-
tions of IFI. However, the European Aspergillus PCR
Initiative has made significant advances in the area of stan-
dardization providing recommendations for extraction of
Aspergillus DNA from whole blood [46, 47].
Early Treatment Strategies for IFI
A randomized controlled trial (RCT) comparing a DD-
strategy that guided the administration of anidulafungin
therapy based on a positive BDG result (>80 pg/ml; Fungi-
tell assay) to the administration of anidulafungin empirically
based on physician’s preference reported that BDG levels
were significantly higher in those with an IFI versus those
who had no IFI (117 vs. 28 pg/ml; p<0.001) [58]. Analysis
of test performance indicated that the use of two sequential
BDG results >80 pg/ml had a sensitivity, specificity, PPV
and NPV of 100 %, 75 %, 30 % and 100 %, respectively.
Twenty-one DD-strategy arm patients received anidulafun-
gin as compared to five empiric arm patients. Anidulafungin
was well tolerated and safe. However, a comparison of mor-
tality outcomes was not reported for this trial. Two additional
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RCT have been completed but the results are not published to
date (MSG-01 and INTENSE, www.clinicaltrials.gov). These
trials may provide data to help determine the best management
strategies for IC in the ICU.
Several DD-strategies for IA have been examined. A num-
ber of prospective non-comparative studies have been per-
formed to determine the feasibility of a more targeted
antifungal approach based on positive non-culture based
assays or characteristic imaging findings rather than the tradi-
tional empiric approach of administering antifungal therapy to
all with persistent or recurrent fevers despite broad-spectrum
antibiotics [59–62]. These studies indicate that DD-driven
strategies can reduce empiric antifungal therapy (EAFT) by
up to 78 % (relative reduction), have an excellent NPV
(100 %), don’t miss cases of IA, can reduce antifungal drug
costs (by £52, 839) and identify cases of IFI even in the
absence of persistent fevers. However, these data only provide
an indirect estimate of the impact of DD-strategies.
A number of RCT have been performed comparing a DD-
strategy to the traditional EAFT approach. Cordonnier et al.,
enrolled 293 patients including low-risk patients undergoing
autologous HSCT [63]. Significantly more IFI were diagnosed
in the DD-strategy arm (13 vs. 4; p<0.02) but overall survival
was no different between the arms (95 % vs. 97 %; p=0.12).
On sub-group analysis, in those receiving induction chemother-
apy, non-inferiority in terms of overall survival was not dem-
onstrated in the DD-strategy arm. Overall, there was a
significant reduction in antifungal drug costs in the DD-
strategy (€1470 vs. €2252; p<0.001). In addition, a significant
delay was detected between fever onset and initiation of anti-
fungal therapy in the DD-strategy arm (median 13 vs. 7 days;
p=0.01). However, this may be related to the delay in institut-
ing the DD-strategy until 96-hours of febrile neutropenia de-
spite broad-spectrum antibiotics. Hebart et al., enrolled 403
allogeneic HSCT recipients and randomized them to a PCR-
based DD-strategy versus the traditional EAFT approach [64].
In the PCR-based arm, antifungal therapy was administered if
one PCR assay was positive or if PCR negative they had
persistent febrile neutropenia despite broad-spectrum antibiot-
ics for five days. Significantly more antifungal therapy was
administered in the DD-strategy arm (112 vs. 76; p<0.001)
due, in the main, to the lack of specificity of the DD-strategy
used in this trial. No difference in the number of cases of proven
and probable IFI was detected between the arms. Whilst a
significant mortality benefit was seen for the DD-strategy at
day 30 post allogeneic HSCT, this was not evident at day 100
post transplantation. This finding may be explained by the lack
of intensive monitoring (twice weekly) with PCR beyond day
30. Two further RCT have been published; one reported that a
GM-based DD-strategy reduced EAFT use without decreasing
survival and the second reported that PCR was a poor indictor
of IA early after non-myeloablative SCT. However, both were
small and inadequately powered [65, 66].
Overall, a DD-strategy will replace the EAFT approach
and provides a suitable alternative to broad-spectrum
mould-active prophylaxis but questions regarding types of
non-culture-based assays that should be used, the patient
groups that a DD-strategy should be used in, timing of
implementation of, duration of screening with a DD-
strategy and cost-effectiveness still need to be answered.
Early diagnosis of CM allowing for early treatment
appears to be the most practical approach in resource-
limited settings. Such a strategy involves screening HIV-
infected patients with CD4 counts <100 cells/μL using one
of the cryptococcal antigen assays (i.e., LA, EIA or LFA). If
one of these assays is positive in an asymptomatic patient,
then therapy using fluconazole should be instituted. Such a
strategy has been studied in Uganda and has been shown to
be associated a survival benefit (71 % at 30 months vs. 0 %
if untreated) [67•]. Further, it has been estimated that such a
screening strategy would be cost-effective in the setting of a
prevalence of asymptomatic cryptococcal antigenemia of
greater than 3 %. Currently, the prevalence of cryptococcal
antigenemia in sub-Saharan Africa and South-East Asia is
between 6 and 13 % [68, 69]. Micol et al., compared
primary prophylaxis to a screening approach and found that
primary prophylaxis was more effective when the CD4
count was less than 50 cells/ μL, but screening was a more
cost-effective strategy when the CD4 count was less than
100 cells/μL [69]. The availability of the new LFA, espe-
cially when used as a point-of-care test, may increase the
scope of such a screening strategy by increasing the avail-
ability of the assay and decreasing losses-to-follow-up.
However, before the widespread roll-out of such a screening
strategy occurs a number of barriers need to be overcome
including the training of health-care workers in the use of
the LFA and the administration of fluconazole.
Conclusions
Numerous non-culture-based assays are now widely avail-
able for the diagnosis of IFI. Now, the challenge is how we
integrate these assays into algorithms so that we can best
target antifungal therapy to those who have an IFI and
prevent unnecessary antifungal therapy in those without an
IFI on one hand and on the other hand reduce mortality
through earlier diagnosis.
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